Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells

Anti-Cancer Drugs

Volumn 20, Issue 9, 2009, Pages 800-806

  Cui, Xiangzhen ^a,b,c   Zhou, Shuai ^a   Xu, Huanli ^a   Zhao, Ting ^a   Liu, Aihua ^b   Guo, Xueping ^b   Wang, Fengshan ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Province Hospital   (China)

^c Shandong Institute of Commerce and Technology   (China)

Author keywords

Adriamycin; Hyaluronan oligosaccharides; K562 A02 cells; Reversal effects

Indexed keywords

DOXORUBICIN; HYALURONAN OLIGOSACCHARIDE; HYALURONIC ACID; OLIGOSACCHARIDE; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FLOW CYTOMETRY; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYALURONIC ACID; K562 CELLS; MOLECULAR STRUCTURE; OLIGOSACCHARIDES;

EID: 70349157252     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832f9d85     Document Type: Article

References (22)

1. Toole BP. Hyaluronan in morphogenesis. Semin Cell Dev Biol 2001; 12:79-87.
2. Schroeder JA, Jackson LF, Lee DC, Camenisch TD. Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J Mol Med 2003; 81:392-403.
3. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002; 277:4589-4592.
4. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4:528-539.
5. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006; 85:699-715.
6. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002; 277:41046-41059.
7. Rooney P, Wang M, Kumar P. Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells. J Cell Sci 1993; 105:213-218.
8. Sattar A, Rooney P, Kumar S, Pye D, West DC, Scott I, et al. Application of angiogenic oligosaccharides blood vessel numbers in rat skin. J Invest Dermatol 1994; 103:576-579.
9. Ghatak S, Misra S, Toole BP. Hyaluronan oligosaccharides inhibit anchorageindependent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002; 277:38013-38020.
10. Ward JA, Huang LH, Guo H. Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am J Pathol 2003; 162:1403-1409.
11. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, Miyasaka M. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem 2003; 278: 32259-32265.
12. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 1994; 6:726-733.
13. Entwistle J, Hall CL, Turley EA. HA receptors: regulators of signalling to the cytoskeleton. J Cell Biochem 1996; 61:569-577.
14. Noble PW. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 2002; 21:25-29.
15. Misra S, Ghatak S, Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-Kinase, and ErbB2. J Biol Chem 2005; 280:20310-20315.
16. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug in cancer cells by hyaluronan. J Biol Chem 2003; 278:25285-25292.
17. Toole BP, Ghatak S, Misra S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol 2008; 9:249-252.
18. Lesley J, Hascall VC, Tammi M, Hyman R. Hyaluronan binding by cell surface CD44. J Biol Chem 2000; 275:26967-26975.
19. Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharmaceut Sci 2007; 10:350-357.
20. Zhou SF. Role of multidrug resistance associated proteins in drug development. Drug Discov Ther 2008; 2:305-332.
21. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
22. Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat 2003; 6:129-136.